FDA Approves SUMATRIPTAN — Cipla USA Inc.

Cipla USA Inc announced Friday the approval of its Abbreviated New Drug Application (ANDA) for sumatriptan nasal spray, a generic version of the branded migraine treatment. This regulatory milestone enables the company to broaden its portfolio in the acute migraine market, potentially capturing significant market share amidst the anticipated loss of patent protection for the branded original.